IL175032A0 - Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same - Google Patents

Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same

Info

Publication number
IL175032A0
IL175032A0 IL175032A IL17503206A IL175032A0 IL 175032 A0 IL175032 A0 IL 175032A0 IL 175032 A IL175032 A IL 175032A IL 17503206 A IL17503206 A IL 17503206A IL 175032 A0 IL175032 A0 IL 175032A0
Authority
IL
Israel
Prior art keywords
nad
administering
methods
same
pharmaceutical formulations
Prior art date
Application number
IL175032A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL175032A0 publication Critical patent/IL175032A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL175032A 2003-10-28 2006-04-20 Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same IL175032A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51507703P 2003-10-28 2003-10-28
PCT/US2004/035129 WO2005044187A2 (en) 2003-10-28 2004-10-22 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same

Publications (1)

Publication Number Publication Date
IL175032A0 true IL175032A0 (en) 2008-04-13

Family

ID=34572801

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175032A IL175032A0 (en) 2003-10-28 2006-04-20 Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same

Country Status (6)

Country Link
US (1) US20070053843A1 (enExample)
EP (1) EP1686960A4 (enExample)
JP (1) JP2007509941A (enExample)
CA (1) CA2543482A1 (enExample)
IL (1) IL175032A0 (enExample)
WO (1) WO2005044187A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909788A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
WO2011093815A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
TR201000685A2 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
US20150165037A1 (en) * 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
AU2014261538A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
US9918938B2 (en) 2013-09-30 2018-03-20 Daiichi Sankyo Company, Limited Selective production method for D-mannitol α-form crystal using spray-drying method
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2016037166A1 (en) * 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
EP3506894B1 (en) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
JP2023520580A (ja) 2020-04-06 2023-05-17 ザ ジェネラル ホスピタル コーポレイション コロナウイルス誘発炎症状態の処置方法
WO2022146914A1 (en) 2020-12-28 2022-07-07 The General Hospital Corporation Cromolyn derivatives and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
EP0211595B1 (en) * 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
HU213221B (en) * 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
SI0820279T1 (en) * 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
CA2218179A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for beclomethasone dipropionate
BR9604978A (pt) * 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador com dose medida
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
JPH11509434A (ja) * 1995-04-14 1999-08-24 グラクソ、ウェルカム、インコーポレーテッド サルメテロール用計量投与用吸入器
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9626960D0 (en) * 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
GB9700226D0 (en) * 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
DE69828155T2 (de) * 1997-03-20 2005-12-22 Schering Corp. Herstellung von pulveragglomeraten
EP0876814A1 (en) * 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
GB2329939A (en) * 1997-06-26 1999-04-07 Glaxo Group Ltd Self-lubricating valve stem for aerosol containers
DK1283036T3 (da) * 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
DE60103276T2 (de) * 2000-02-17 2005-06-23 Teva Pharmaceutical Industries Ltd. Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält

Also Published As

Publication number Publication date
US20070053843A1 (en) 2007-03-08
WO2005044187A3 (en) 2006-03-23
WO2005044187A2 (en) 2005-05-19
EP1686960A4 (en) 2007-03-07
JP2007509941A (ja) 2007-04-19
EP1686960A2 (en) 2006-08-09
CA2543482A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
EP1686960A4 (en) INHALABLE PHARMACEUTICAL PREPARATIONS EMPLOYING LACTOSE ANHYDRATE, AND METHODS OF ADMINISTERING SAID PREPARATIONS
AU156078S (en) Set of cannula heads
EP1487411A4 (en) THERAPEUTIC FORMULATIONS SUPPORTED BREATHABLE
ZA200410229B (en) Administration of therapeutic viruses
AU2003296897A8 (en) Pharmaceutical formulations of camptothecine derivatives
AU2003215334A1 (en) Inhalable formulations for sustained release
AU2003220348A1 (en) Ct integrated respiratory monitor
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
IL183587A0 (en) Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP1965823A4 (en) METHOD FOR THE ADMINISTRATION OF HYPOGLYKEMIC AGENTS
EP1551426A4 (en) PROCESS FOR THE ADMINISTRATION OF FGF18
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2002362774A1 (en) Cyclosporin analogs for the treatment of lung diseases
EP1551425A4 (en) THERAPEUTIC FORMULATIONS
EP1534295A4 (en) FORMULATIONS AND METHODS OF ADMINISTRATION OF CEPHALOTAXINS, INCLUDING HOMOHARRINGTONIN
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
SI1487828T1 (sl) Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
IL175014A0 (en) Method of administering therapeutic injections
EP1594959A4 (en) THERAPEUTIC METHOD AND COMPOSITIONS FOR TOPICAL ADMINISTRATION
GB0202900D0 (en) Novel formulations of drugs
IL166337A0 (en) Oral administration of calctionin
IL176404A (en) Pharmaceutical composition of vinflunine which is intended for parenteral administration, preparation method thereof and use of same
IL173110A0 (en) Semi-solid formulations for the oral administration of taxoids
ZA200506750B (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluroanilino) phenylacetic acid
EP1740541A4 (en) THERAPEUTIC FORMULATIONS OF DESOXYEPOTHILONES